Migraines affect 10% of the population – with women affected 3 times more than men. A first in class biologic, erenumab (Aimovig®), has been approved for migraine prevention. Erenumab is a monoclonal antibiody that binds to and blocks calcitonin gene-related receptors. In patients with episodic migraines (4 to 14 monthly), erenumab reduced migraine frequency by 1 to 2 days per month after 3 to 6 months of treatment. Patients with chronic migraines (at least 15 headaches and 8 migraines monthly) experienced an average of 2.5 fewer migraine days per month after 3 months of treatment.
Erenumab is self-injected subcutaneously (70 or 140 mg) once monthly. The most common side effects are injection site reaction (5-6%) and constipation (1-3%). The needle cover of the syringe and autoinjector contain latex, which may cause a reaction in latex-sensitive patients.
• FDA News Release; published online May 2018.